US trial to assess value of oxygen for COPD
This article was originally published in Clinica
US Medicare is teaming up with the National Heart, Lung and Blood Institute in sponsoring a 3,500 patient clinical trial - the largest ever - on the effectiveness and safety of long-term, home oxygen therapy for chronic obstructive pulmonary disease (COPD).
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.